financetom
Business
financetom
/
Business
/
Toyota global output skids in June, dragged down by Japan and China
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Toyota global output skids in June, dragged down by Japan and China
Jul 29, 2024 10:06 PM

TOKYO, July 30 (Reuters) - Toyota's ( TM ) global

production tumbled in June, down for a fifth straight month with

the automaker hit hard by a certification scandal in its home

market and a fierce price war in China.

Output worldwide for Japan's biggest automaker slid 12.9% to

795,862 vehicles, the sharpest decline since December 2022.

In its home market, output plunged 18.8% after the transport

ministry found irregularities in applications by Toyota ( TM ) and

other automakers to certify certain models in a widening of an

auto safety scandal.

In China, where domestic electric vehicle makers like BYD

have rapidly gained market share and have

aggressively cut prices, production fell 21.7% - marking the

fifth month in a row where Toyota's ( TM ) output has declined by 20%

or more.

Production in North America fell 6.2% while in Europe it

dropped 6.6% due to fewer production days compared to last year.

Toyota's ( TM ) worldwide sales fell 5.1% during the month, hurt by

declines in Japan and China.

The automaker is due to report first-quarter financial

results on Thursday. It is expected to log a 21% rise in

operating profit from a year earlier to 1.35 trillion yen ($8.7

billion), according to an LSEG consensus estimates from six

analysts, helped by a weaker yen and robust demand for hybrid

vehicles in the United States.

During the first six months of this year, the automaker's

global production fell 5% while worldwide sales dipped 0.9%.

Both sales and production figures include the luxury Lexus

brand.

($1 = 154.0800 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO Previews AGF Management's Q2
BMO Previews AGF Management's Q2
Jun 20, 2024
01:38 PM EDT, 06/20/2024 (MT Newswires) -- AGF Management reports its second quarter results on June 26. BMO is looking for second quarter EBITDA of $35.3 million ($35.5 million consensus), and earnings per share of $0.34 (consensus $0.34). Analyst Tom MacKinnon expects net outflows of $50 million, reflecting the challenging environment in the mutual fund industry. After recently increasing our...
Omai Gold Mines Raises About $13 Million Via Brokered Private Placement
Omai Gold Mines Raises About $13 Million Via Brokered Private Placement
Jun 20, 2024
01:31 PM EDT, 06/20/2024 (MT Newswires) -- Omai Gold Mines ( OMGGF ) on Thursday said it raised $13 million in a private placement of shares. The company said it placed 108.33-million shares priced at $0.12 in the financing. The company plans to use the proceeds for exploration and development, and general working capital purposes. Omai shares were last seen...
United Airlines Flight Reportedly Forced to Return to Departure Location After Engine Issues
United Airlines Flight Reportedly Forced to Return to Departure Location After Engine Issues
Jun 20, 2024
01:29 PM EDT, 06/20/2024 (MT Newswires) -- United Airlines (UAL) Flight 325 on Thursday had to return to Bradley Airport in Connecticut after a portion of the engine's sound-dampening outer liner fell on the runway and the aircraft experienced an issue with its engine, according to media reports. The plan was reportedly Airbus aircraft and was headed to Denver International...
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump
Jun 20, 2024
01:31 PM EDT, 06/20/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday its experimental twice-yearly Lenacapavir shot to prevent HIV was 100% effective in women in a late-stage trial, sending the drugmaker's shares soaring. The Purpose 1 phase 3 trial is assessing the safety and efficacy of Lenacapavir for pre-exposure prophylaxis, or PrEP, and once-daily oral Descovy in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved